Protalix BioTherapeutics Showcases Impressive PRX-115 Findings
Protalix BioTherapeutics, Inc. (NYSE American: PLX), is making headway in the biopharmaceutical landscape with the presentation of its Phase I clinical trial data for PRX-115. This product candidate is an innovative PEGylated uricase aimed at treating uncontrolled gout. The company will share these valuable insights in a late-breaking poster at the upcoming American College of Rheumatology Convergence 2024.
Key Details on PRX-115 Presentation
The presentation, titled 'Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels', will occur during a significant session dedicated to late-breaking posters. This event is scheduled for November 18, at 10:30 AM to 12:30 PM Eastern Standard Time.
Who Will Present?
Orit Cohen Barak, Ph.D., from Protalix Ltd., will present the findings. Researchers look forward to insights drawn from the clinical trial outcomes.
Protalix's Innovative Approach
Protalix BioTherapeutics has distinguished itself through its proprietary ProCellEx plant cell-based protein expression system, allowing for the production of therapeutic proteins. This method is pivotal in the development of PRX-115 and represents a novel approach in biopharmaceutical manufacturing.
Milestones in Biopharmaceutical Development
In a landmark move, Protalix became the first company to gain FDA approval for a protein produced via its plant cell-based expression system. This pioneering achievement not only showcases the capability of the ProCellEx technology but also sets a precedent for future therapeutic developments.
Products in the Pipeline
Alongside PRX-115, Protalix is advancing several candidates targeting prevalent medical issues. This includes PRX–119, which is focused on NETs-related diseases, demonstrating the company’s commitment to addressing substantial gaps in treatment options.
Collaborative Efforts and Future Endeavors
Protalix continues to strengthen its market position through strategic partnerships. Its collaboration with Chiesi Farmaceutici S.p.A. is aimed at the global advancement and commercialization of Elfabrio, which secured approval from the FDA and the European Medicines Agency.
Contact Information
Investors seeking more details on Protalix's developments can reach out to Mike Moyer, Managing Director at LifeSci Advisors, at +1-617-308-4306 or via email.
Frequently Asked Questions
What is PRX-115?
PRX-115 is a recombinant PEGylated uricase being developed for the treatment of uncontrolled gout.
When is the presentation about PRX-115?
The presentation will take place on November 18, during the ACR Convergence 2024 event.
Who is presenting the PRX-115 data?
Orit Cohen Barak, Ph.D. from Protalix Ltd., will be the presenting author.
What are the key benefits of the ProCellEx technology?
This technology allows for the efficient production of recombinant therapeutic proteins, offering a novel method of manufacturing at industrial scale.
What other products is Protalix developing?
In addition to PRX-115, Protalix is developing PRX–119 and other candidates aimed at various therapeutic markets.